Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

CVOT Summit Report 2023 : new cardiovascular, kidney, and metabolic outcomes

Schnell, Oliver ; Barnard-Kelly, Katharine ; Battelino, Tadej ; Ceriello, Antonio ; Larsson, Helena Elding LU ; Fernández-Fernández, Beatriz ; Forst, Thomas ; Frias, Juan Pablo ; Gavin, James R. and Giorgino, Francesco , et al. (2024) In Cardiovascular Diabetology 23(1).
Abstract

The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online... (More)

The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cardiovascular disease, CGM, Chronic kidney disease, Diabetes, Finerenone, GLP-1 RA, Guidelines, Heart failure, MASLD, NAFLD, Obesity, SGLT2 inhibitor, Teplizumab
in
Cardiovascular Diabetology
volume
23
issue
1
article number
104
publisher
BioMed Central (BMC)
external identifiers
  • pmid:38504284
  • scopus:85188142815
ISSN
1475-2840
DOI
10.1186/s12933-024-02180-8
language
English
LU publication?
yes
id
563183ef-14af-49b8-84bc-ee98574feb84
date added to LUP
2024-03-27 14:02:50
date last changed
2024-04-24 18:02:41
@misc{563183ef-14af-49b8-84bc-ee98574feb84,
  abstract     = {{<p>The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).</p>}},
  author       = {{Schnell, Oliver and Barnard-Kelly, Katharine and Battelino, Tadej and Ceriello, Antonio and Larsson, Helena Elding and Fernández-Fernández, Beatriz and Forst, Thomas and Frias, Juan Pablo and Gavin, James R. and Giorgino, Francesco and Groop, Per Henrik and Heerspink, Hiddo J.L. and Herzig, Stephan and Hummel, Michael and Huntley, George and Ibrahim, Mahmoud and Itzhak, Baruch and Jacob, Stephan and Ji, Linong and Kosiborod, Mikhail and Lalic, Nebosja and Macieira, Sofia and Malik, Rayaz A. and Mankovsky, Boris and Marx, Nikolaus and Mathieu, Chantal and Müller, Timo D. and Ray, Kausik and Rodbard, Helena W. and Rossing, Peter and Rydén, Lars and Schumm-Draeger, Petra Maria and Schwarz, Peter and Škrha, Jan and Snoek, Frank and Tacke, Frank and Taylor, Bruce and Jeppesen, Britta Tendal and Tesfaye, Solomon and Topsever, Pinar and Vilsbøll, Tina and Yu, Xuefeng and Standl, Eberhard}},
  issn         = {{1475-2840}},
  keywords     = {{Cardiovascular disease; CGM; Chronic kidney disease; Diabetes; Finerenone; GLP-1 RA; Guidelines; Heart failure; MASLD; NAFLD; Obesity; SGLT2 inhibitor; Teplizumab}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Cardiovascular Diabetology}},
  title        = {{CVOT Summit Report 2023 : new cardiovascular, kidney, and metabolic outcomes}},
  url          = {{http://dx.doi.org/10.1186/s12933-024-02180-8}},
  doi          = {{10.1186/s12933-024-02180-8}},
  volume       = {{23}},
  year         = {{2024}},
}